 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper129th MAINE LEGISLATURE
FIRST REGULAR SESSION-2019
Legislative Document No. 1429
S.P. 441 In Senate,  March  28, 2019
An Act  To Fund Opioid Use Disorder Prevention and Treatment
Reference to the Committee on Health  and Human Services suggested and  ordered printed.
DAREK M.  GRANT
Secretary of the Senate
Presented by President JACKSON of Aroostook.
Cosponsored by Representative McCREIGHT of Harpswell and
Senators: CLAXTON of Androscoggin, DILL of Penobscot,  GRATWICK  of Penobscot,  
SANBORN, H. of Cumberland, VITELLI of  Sagadahoc,  Representatives:  BEEBE-CENTER  
of Rockland, PERRY of Calais.

Page 1 - 129LR1898(01)-11Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  5 MRSA §20010 is enacted to read:
3§20010.  Opioid Use Disorder Prevention and Treatment Fund
41.  Fund established.  The Opioid Use Disorder Prevention and Treatment Fund, 
5referred to in this section as "the fund," is established for the purpose of supporting opioid 
6use disorder analysis, prevention and treatment and is administered by the department.  
7The fund consists of money received from proceeds from the prescription opioid impact 
8fee under subsection 3 and appropriations, allocations and contributions from private and 
9public sources.  The fund must be held separate and apart from all other money, funds 
10and accounts.  Eligible investment earnings credited to the assets of the fund become part 
11of the assets of the fund.  Any unexpended balances remaining in the fund at the end of 
12any fiscal year do not lapse and must be carried forward to the next fiscal year.
132.  Uses of fund proceeds.  The proceeds of the fund must be used for the following 
14purposes:
15A.  Opioid addiction prevention services;
16B.  Opioid addiction treatment services, including:
17(1)  Inpatient and outpatient treatment programs and facilities, including short-
18term and long-term residential treatment programs and sober living facilities;
19(2)  Treating substance use disorder for the underinsured and uninsured; and
20(3)  Research regarding opioid addiction prevention and treatment; and
21C.  The department's reasonable expenses in administering the fund.
22The department shall award grants and contracts from proceeds of the fund to persons and 
23organizations to carry out the purposes of the fund.
243.  Prescription opioid impact fee.  A manufacturer of prescription opioid drugs 
25shall pay a prescription opioid impact fee on prescription opioid drugs manufactured by 
26the manufacturer that are distributed in the State.  The fee under this subsection is 2¢ per 
27morphine milligram equivalent for each prescription opioid drug of the manufacturer 
28distributed in the State.  The department shall collect this fee pursuant to rules adopted by 
29the department and deposit the proceeds from the fee into the fund.
304.  Rules.  The department shall adopt rules to carry out the purposes of this section.  
31Rules adopted under this subsection are routine technical rules as defined in chapter 375, 
32subchapter 2-A.
33SUMMARY
34This bill establishes the Opioid Use Disorder Prevention and Treatment Fund 
35administered by the Department of Health and Human Services for the purpose of 
36supporting opioid use disorder analysis, prevention and treatment.  The fund is funded by 
37a 2¢ fee per morphine milligram equivalent assessed against prescription opioid drug 
Page 2 - 129LR1898(01)-11manufacturers for prescription opioid drugs distributed in the State as well as 
2appropriations, allocations and contributions from private and public sources.
